In a repeat setback, Neurocrine flags a failure for Tourette syndrome study — shares sink
Shares of Neurocrine $NBIX got hammered Tuesday morning after the biotech conceded that its Phase IIb study of valbenazine for Tourette syndrome had flopped. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
